Boehringer Ingelheim Corporation and Eli Lilly and Company Release: Real Time Assessm Results of New Meta-Analysis Regarding CV Events in Linagliptin Phase 3 Trials Presented at American Diabetes Association

Published: Jun 24, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

For Non-U.S. and Non-UK media Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with an increased risk of cardiovascular events in the treatment of Type 2 Diabetes (T2D), versus a number of comparators (placebo, glimepiride and voglibose). These findings were presented at the American Diabetes Association (ADA) 73rd Scientific Sessions®.1

Help employers find you! Check out all the jobs and post your resume.

Back to news